Another recent phase 1 trial of AdV-tk, an oncolytic AdV engineered to express HSV thymidine kinase (HSV-tk), demonstrated a safe RT and OVT combination in paediatric high-grade gliomas [84]. The gene discussed is TKT; the disease is glioma.